MayMag Biologics Expands Global CDMO 506(e) Sterile Fill-Finish Operations to Dramatically Reduce Healthcare Costs and Expand Affordable Diabetic Care in Underprivileged Nations
DALLAS-GARLAND, TX — MayMag Biologics, an FDA-registered 506(e) large-scale biopharmaceutical manufacturing facility and Contract Development and Manufacturing Organization (CDMO), today announced a global strategic expansion of its sterile fill-finish operations. Designed to directly address the worldwide diabetes crisis, MayMag Biologics is partnering with approved Active Pharmaceutical Ingredient (API) and biosimilar manufacturers to produce high-quality, low-cost diabetic biosimilar treatments for worldwide distribution. By leveraging scalable 506(e) outsourcing infrastructure, advanced aseptic filling technologies, and primary packaging capabilities across reusable auto-injectors/auto-pens, multi-dose vials, and emerging oral solid dosages, MayMag Biologics aims to remove cost barriers and deliver essential life-saving insulins to low- and middle-income countries (LMICs). Expanding Access to Next-Generation and Essential Biosimilar Insulins Through collaborative par...